Healthcare
Phio Pharma
Recorded March 18, 2026
Phio Pharmaceuticals (NASDAQ: PHIO) has developed a differentiated, precision approach to treating skin cancer.
Phio Pharmaceuticals (NASDAQ: PHIO) has developed a differentiated, precision approach to treating skin cancer.
Xgene is using its proprietary conjugate platform technology to provide highly effective non-opioid relief for acute and chronic pain
Coretag has built a patented Tumor Necrosis Targeting Platform to precisely guide radiotherapeutics for the treatment of many solid cancers.
A proven, proprietary, scalable technology for converting organic waste into the building blocks of Sustainable Aviation Fuel
Hall of Giants will be a first-of-its-kind cultural institution devoted to celebrating America’s entrepreneurial spirit.
An entertainment opportunity that is the nexus of theatre, nightlife, dining, post-modern design, and community
A precision neuroscience company developing treatments for children with epilepsy, autism, and other severe neurodevelopmental disorders
MiMesis boosts watch time and ROI of streaming libraries with its proprietary AI-powered dubbing technology
Ultrashort pulse lasers deliver intense bursts of energy and can destroy optical and infrared sensors on drones in less than a second
Phio Pharmaceuticals (NASDAQ: PHIO) has developed a differentiated, precision approach to treating skin cancer.
Xgene is using its proprietary conjugate platform technology to provide highly effective non-opioid relief for acute and chronic pain
AvenCell Therapeutics is pioneering the next generation of cancer treatment with powerful, persistent, and switchable allogeneic CAR-T therapies